



<b>Title</b>	<b>Continuous entecavir for treatment-naïve Chinese chronic hepatitis B in the real world setting: the six-year results</b>
<b>Author(s)</b>	<b>Seto, WK; Lam, YF; Liu, KSH; Mak, LY; Ko, MKL; Fung, J; Lai, CL; Yuen, RMF</b>
<b>Citation</b>	<b>The 2014 Gastroenterology Conference: Digestive Disease Week (DDW 2014), Chicago, IL., 3-6 May 2014. In Gastroenterology, 2014, v. 146 n. 5, suppl. 1, p. S963-S964, abstract Su1016</b>
<b>Issued Date</b>	<b>2014</b>
<b>URL</b>	<b><a href="http://hdl.handle.net/10722/198626">http://hdl.handle.net/10722/198626</a></b>
<b>Rights</b>	<b>NOTICE: this is the author's version of a work that was accepted for publication in Gastroenterology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Gastroenterology, v. 146 n. 5, suppl. 1, May 2014. DOI: 10.1016/S0016-5085(14)63507-1</b>

## **Su1016 Continuous Entecavir for Treatment-Naive Chinese Chronic Hepatitis B in the Real World Setting: The Six-Year Results**

*Wai-Kay Seto, Yuk-Fai Lam, Sze Hang Kevin Liu, Lung-Yi Mak, Kwan-Lung Michael Ko, James Fung, Ching-Lung Lai, Man-Fung Yuen*

**BACKGROUND:** There is a paucity of data on uninterrupted entecavir for treatment-naive chronic hepatitis B (CHB) beyond 5 years. **METHODS:** Treatment-naive Chinese CHB patients were treated continuously with entecavir 0.5mg daily in the real world setting for up to 6 years. The cumulative rates of hepatitis B e antigen (HBeAg) seroconversion, alanine aminotransferase (ALT) normalization, DNA undetectability, virologic breakthrough (>1 log HBV DNA increase from the nadir) and genotypic resistance to entecavir were determined. HBV DNA levels were measured by Roche Taqman real time PCR assay (lower limit of detection: 20 IU/mL). Resistance profile was determined by line probe assay (LiPA, Innogenetics NV, Gent, Belgium) for patients with detectable HBV DNA. **RESULTS:** 222 Chinese CHB patients (median age 45 years, 70.7% male) were recruited. 222, 188, 173, 170, 164 and 155 patients were followed up for 1, 2, 3, 4, 5 and 6 years respectively. The cumulative rate of HBV DNA undetectability up to year 6, determined by the Kaplan-Meier method, was 98.7%. Among patients with follow-up beyond two years, 30 (17.3%) had partial virologic response, defined as detectable HBV DNA at year 1, of which 27 (90%) subsequently developed persistent HBV DNA undetectability. The cumulative rate of ALT normalization up to year 6 was 95.0%. 90 patients (40.5%) were HBeAg-positive at baseline, and the cumulative HBeAg seroconversion rate up to year 6 was 76.1%. 2 patients developed HBsAg seroclearance at years 2 and 6 respectively; the cumulative rate of HBsAg seroclearance up to year 6 was 1.2%. The cumulative rate of virologic breakthrough was 6.3% (n=6). 2 patients developed entecavir signature mutations at year 3 (rt180M/rt204V/rt184S/C/G/A) and 4 (rt180M/rt204V/rt184I/F/M) respectively. The cumulative rate of entecavir resistance up to year 6 was 1.2%. There were no serious adverse events related to entecavir. **CONCLUSION:** Entecavir is a potent and safe nucleoside analogue suitable for long-term use, with only very low rates of resistance. Majority of patients with partial virologic response eventually achieved successful long-term virologic suppression. 6 years of therapy only achieved a low rate of HBsAg seroclearance, indicating new agents capable of achieving strong HBsAg reduction are needed to enhance current treatment regimens for CHB.